Table 2. Expression of CD95 and CD95L on... | American Society of Hematology

Table 2.

Expression of CD95 and CD95L on Leukemic LGL

Samples	Phenotype (%)
Samples	CD95	CD57	CD57/CD95^*	CD95L
PBMC	35 ± 11	6 ± 2	32 ± 12	2 ± 1
PBMC post-PHA/IL-2	94 ± 3	9 ± 2	90 ± 3	42 ± 5
CD3⁺ LGL leukemia (patient no.)
1	96	44	80	90
2	78	30	62	43
3	85	74	85	ND
4	95	65	84	44
5	95	52	93	90
6	78	33	77	79
7	84	76	84	35
8^†	96	15	72	80
9	91	41	82	50
10^‡	87	12	64	89
11	82	38	63	88
Mean ± SD	88 ± 7	44 ± 22	77 ± 10	69 ± 23

Samples	Phenotype (%)
Samples	CD95	CD57	CD57/CD95^*	CD95L
PBMC	35 ± 11	6 ± 2	32 ± 12	2 ± 1
PBMC post-PHA/IL-2	94 ± 3	9 ± 2	90 ± 3	42 ± 5
CD3⁺ LGL leukemia (patient no.)
1	96	44	80	90
2	78	30	62	43
3	85	74	85	ND
4	95	65	84	44
5	95	52	93	90
6	78	33	77	79
7	84	76	84	35
8^†	96	15	72	80
9	91	41	82	50
10^‡	87	12	64	89
11	82	38	63	88
Mean ± SD	88 ± 7	44 ± 22	77 ± 10	69 ± 23

Abbreviations: PBMC, peripheral blood mononuclear cells from normal controls, n = 6; ND, not determined.

Percentage of CD57⁺ cells expressing CD95 is indicated.

Sixty-one percent of the cells were CD16⁺.

Thirty-eight percent of the cells were CD56⁺.